Small Molecules
Our small molecule manufacturing capabilities span complex, multi-step chemical synthesis supporting both early clinical trials and commercial supply. Operating under stringent cGMP standards and robust quality systems, our facilities handle diverse synthetic transformations, chiral resolutions, and advanced crystallizations. We focus on high-yield, atom-economical processes that ensure batch-to-batch reproducibility, comprehensive impurity control, and dependable supply chain resilience.
Our manufacturing network comprises 3 production trains with a total installed capacity of 400 KL, featuring reactor sizes ranging from 250 L to 12,000 L.
High Potent APIs (HPAPIs)
We deliver tailored containment infrastructure designed specifically for cytotoxic, cytostatic, and highly active compounds requiring Occupational Exposure Limits (OEL) down to nanogram levels (SafeBridge Category 3/4). Featuring state-of-the-art barrier isolators, split butterfly valves, dedicated negative-pressure HVAC air handling, and closed-system transfers, our HPAPI suites safeguard operators and prevent cross-contamination while ensuring high analytical purity for oncology and high-potency drug candidates.
The facility is equipped with reactor sizes ranging from 2L to 100 L, with Stainless Steel, Glass-Lined, and Hastelloy MOCs to support diverse synthetic routes.
Liquid-Phase Peptide Synthesis (LPPS)
For scalable peptide therapeutics, Liquid-Phase Peptide Synthesis (LPPS) provides an atom-economical, cost-effective alternative to solid-phase approaches. Our process design enables real-time reaction monitoring and simple intermediate purification, significantly curtailing excess coupling reagents and organic solvent volumes. This platform is ideal for short peptides, peptide fragments, and specialized peptidomimetics requiring robust, commercial-scale production with high diastereomeric purity.
Linkers & GalNAc Conjugation Platforms
Accelerate targeted therapeutic delivery with our high-purity bioconjugation technologies. We specialize in the custom synthesis and scale-up of cleavable and non-cleavable linkers (e.g., Val-Cit, ester, disulfide) for Antibody-Drug Conjugates (ADCs), alongside high-affinity N-acetylgalactosamine (GalNAc) clusters for liver-targeted siRNA and antisense therapies. Our synthesis pathways deliver precise control over polydispersity, spacer length, and functional trigger integrity for seamless downstream conjugation.